In the rat, pebulate was readily absorbed, distributed, metabolized and eliminated, primarily in urine, feces, and CO2. Less than 3% was detected in total tissues. Major metabolites were identified in the urine as pebulate mercapturate, hydroxylated pebulate, butylamine and ethylbutylamine, hydroxyethylbutylamine, and hydroxylated pebulate mercapturate.
Analysis of /adult rat/ urine samples revealed an extensive labeling of urinary constituents, such as urea, and many amino acids. ... Identification of labeled volatile cmpd in the urine revealed the presence of 0.3-2.8% as unchanged pebulate, and also a small amount of (14)C propylmercaptan and (14)C propanol. These results indicated a hydrolytic cleavage of the thiocarbamate molecule to propylmercaptan which was further converted to propanol by transthiolation. The propanol was then oxidized to a C-3 acid and entered a metabolic pool. Hydrolysis of the urine sample with strong acid converted some nonvolatile labeled metabolites to steam-volatile, isooctane-extractable metabolites, indicating that the pebulate molecule had undergone conjugation.
Pebulate is metabolized to the sulfoxide by mouse liver microsome-NADPH system, living mice, and photolysis. It is metabolized to sulfoxone and carbon dioxide in living mice. After oxidation to the sulfoxide, cleavage by the GSH-S-transferase system occurred with...pebulate. Mercaptans were released. /From table/
As a general rule, thiocarbamates can be absorbed via the skin, mucous membranes, and the respiratory and gastrointestinal tracts. They are eliminated quite rapidly, mainly via expired air and urine. Two major pathways exist for the metabolism of thiocarbamates in mammals. One is via sulfoxidation and conjugation with glutathione. The conjugation product is then cleaved to a cysteine derivative, which is metabolized to a mercapturic acid compound. The second route is oxidation of the sulfur to a sulfoxide, which is then oxidized to a sulfone, or hydroxylation to compounds that enter the carbon metabolic pool.
Some thiocarbamates (EPTC, Molinate, Pebulate, and Cycloate) share a common mechanism of toxicity, i.e. the inhibition of acetylcholinesterase. An acetylcholinesterase inhibitor suppresses the action of acetylcholine esterase. Because of its essential function, chemicals that interfere with the action of acetylcholine esterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses. Headache, salivation, nausea, vomiting, abdominal pain and diarrhea are often prominent at higher levels of exposure. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop.
来源:Toxin and Toxin Target Database (T3DB)
毒理性
致癌性证据
癌症分类:不太可能对人类致癌
Cancer Classification: Not Likely to be Carcinogenic to Humans
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌物分类
对人类不具有致癌性(未被国际癌症研究机构IARC列名)。
No indication of carcinogenicity to humans (not listed by IARC).
Data concerning the effects of thiocarbamates on man are scarce. However, cases of irritation and sensitization have been observed among agricultural workers. Some thiocarbamates, e.g., molinate, have an effect on sperm morphology and, consequently, on reproduction. However, no teratogenic effects have been observed. The results of mutagenicity studies have shown that thiocarbamates containing dichloroallyl groups are highly mutagenic. Some thiocarbamates are acetylcholine esterase inhibitors. Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.
In the rat, pebulate was readily absorbed, distributed, metabolized and eliminated, primarily in urine, feces, and CO2. Less than 3% was detected in total tissues. Major metabolites were identified in the urine as pebulate mercapturate, hydroxylated pebulate, butylamine and ethylbutylamine, hydroxyethylbutylamine, and hydroxylated pebulate mercapturate.
...About 50% of /SRP: labeled/ compound administered to rats was expired as carbon dioxide in three days, about 25% /SRP: of labeled compound/ was excreted in the urine and 5% in the feces.
In adult rats...tissue accumulation studies showed that pebulate was absorbed and distributed throughout whole body with highest concentrations in the liver and blood. The accumulation of radioactivity in most internal organs increased with increasing dosages... This relationship is approximately linear between the dosages used. The biological half life in these organs was between 2-3.6 days.
Pebulate, EPTC, cycloate, butylate and vernolate (each at 0.3 mg, replicated 4 times,) were administered one time only as emulsifiable concentrates (1/100 aqueous dilution of a (14)C-labelled) to non-occluded skin of CD Crl:CD(SD)BR rats (10/compound). Evaluation was 10 hours after treating. Recovery of radioactivity averaged 76.1%, 93.7%, 94.9%, 95.4% and 92.9% for EPTC, cycloate, butylate, pebulate and vernolate, respectively. The high proportion of the applied dose for all 5 thiocarbamates was from the non-occlusive cover, indicating that a large percentage of the applied dose volatilized from the skin surface (captured by active carbon filters). EPTC recovery was comparatively lower due to its greater volatility and the volatility occurred during dosing, rather than during the 10 hour exposure. Cycloate absorption (material found in systemic circulation) was 15.90%, compared with 9.9%, 7.35%, 5.76% and 4.0% for pebulate, vernolate, EPTC and butylate, respectively. For pebulate, radioactivity was recovered in the following percentages: skin wash, 4.26%; non-occlusive cover, 79.37%; application site, 1.72%; untreated skin, 0.09%; total not absorbed, 85.45%; urine, 3.11%; feces, 0.14%; cage wash, 0.40%; carbon dioxide, 1.32%; expired volatiles, 0.14%; carcass, 4.81%; total absorbed dose, 9.90%; total recovered, 95.35%.
1.周国泰,化学危险品安全技术全书,化学工业出版社,1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编,化学品毒性法规环境数据手册,中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
[EN] 3-[(HYDRAZONO)METHYL]-N-(TETRAZOL-5-YL)-BENZAMIDE AND 3-[(HYDRAZONO)METHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE DERIVATIVES AS HERBICIDES<br/>[FR] DÉRIVÉS DE 3-[(HYDRAZONO))MÉTHYL]-N-(TÉTRAZOL-5-YL)-BENZAMIDE ET DE 3-[(HYDRAZONO)MÉTHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE UTILISÉS EN TANT QU'HERBICIDES
申请人:SYNGENTA CROP PROTECTION AG
公开号:WO2021013969A1
公开(公告)日:2021-01-28
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4, R5 and R6 are as described herein. The invention further relates to compositions comprising said compounds, to methods of controlling weeds using said compositions, and to the use of compounds of Formula (I) as a herbicide.
[EN] HERBICIDALLY ACTIVE HETEROARYL-S?BSTIT?TED CYCLIC DIONES OR DERIVATIVES THEREOF<br/>[FR] DIONES CYCLIQUES SUBSTITUÉES PAR HÉTÉROARYLE À ACTIVITÉ HERBICIDE OU DÉRIVÉS DE CELLES-CI
申请人:SYNGENTA LTD
公开号:WO2011012862A1
公开(公告)日:2011-02-03
The invention relates to a compound of formula (I), which is suitable for use as a herbicide wherein G is hydrogen or an agriculturally acceptable metal, sulfonium, ammonium or latentiating group; Q is a unsubstituted or substituted C3-C8 saturated or mono-unsaturated heterocyclyl containing at least one heteroatom selected from O, N and S, or Q is heteroaryl or substituted heteroaryl; m is 1, 2 or 3; and Het is an optionally substituted monocyclic or bicyclic heteroaromatic ring; and wherein the compound is optionally an agronomically acceptable salt thereof.
Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
申请人:Dow AgroSciences LLC
公开号:US20180279612A1
公开(公告)日:2018-10-04
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).
3-AMINOXALYL-AMINOBENZAMIDE DERIVATIVES AND INSECTICIDAL AND MITICIDAL AGENTS CONTAINING SAME AS ACTIVE INGREDIENT
申请人:Usui Shuichi
公开号:US20120022263A1
公开(公告)日:2012-01-26
The present invention herein provides a 3-aminooxalylaminobenzamide derivative which is used as an insecticide or miticide.
The 3-aminooxalylaminobenzamide derivative is one represented by the following general formula [1]:
(R
1
and R
2
each represent, for instance, a C
1
to C
3
alkoxy group or a C
1
to C
3
haloalkoxy group; R
3
and R
4
each represent, for instance, a C
1
to C
8
alkyl group or a C
1
to C
8
haloalkyl group; R
5
represents, for instance, a C
1
to C
5
haloalkyl group; R
6
and R
7
each represent, for instance, a hydrogen atom or a C
1
to C
5
alkyl group; Y represents, for instance, a hydrogen atom or a halogen atom; Z represents, for instance, a hydrogen atom; n is an integer ranging from 0 to 4 and m is an integer ranging from 0 to 2).